Your session is about to expire
← Back to Search
Other
ORP-101 50 mg for Irritable Bowel Syndrome
Phase 2
Waitlist Available
Research Sponsored by OrphoMed, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights
Summary
This trial tests ORP-101, a new medication, to see if it can help people with IBS-D by improving stool consistency and reducing abdominal pain. Adults with IBS-D will take the medication daily for a few months, and researchers will monitor their symptoms.
Eligible Conditions
- Irritable Bowel Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Percentage of Participants Who Are Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores
Secondary outcome measures
Change from Baseline in Daily Abdominal Bloating Scores
Change from Baseline in Daily Abdominal Discomfort Scores
Cathartics
+6 moreSide effects data
From 2016 Phase 1 & 2 trial • 104 Patients • NCT0265567910%
Pruritus
10%
Nasopharyngitis
5%
Application site pain
5%
Procedural dizziness
5%
Cellulitis
5%
Decreased appetite
5%
Chest pain
5%
Sunburn
5%
Diarrhoea
5%
Hypothyroidism
5%
Administration site pruritus
5%
Fatigue
100%
80%
60%
40%
20%
0%
Study treatment Arm
VTP- 38543 0.05%
Vehicle Without Transcutol®P
VTP- 38543 0.15%
VTP-38543 1%
Vehicle With Transcutol®P
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: ORP-101 50 mgExperimental Treatment1 Intervention
ORP-101 (50 mg) once daily
Group II: ORP-101 100 mgExperimental Treatment1 Intervention
ORP-101 (100 mg), once daily
Group III: PlaceboPlacebo Group1 Intervention
Matching placebo, once daily
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ORP-101
2019
Completed Phase 2
~330
Find a Location
Who is running the clinical trial?
PPDIndustry Sponsor
161 Previous Clinical Trials
36,659 Total Patients Enrolled
OrphoMed, Inc.Lead Sponsor
Share this study with friends
Copy Link
Messenger